Tourmaline Bio (TRML) Stock Forecast & Price Target

$17.95

+0.83 (+4.85%)

(As of 07/26/2024 ET)

Tourmaline Bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for Tourmaline Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for TRML.

Consensus Price Target

$61.80
244.29% Upside

High Forecast	$74.00
Average Forecast	$61.80
Low Forecast	$48.00

According to the 6 analysts' twelve-month price targets for Tourmaline Bio, the average price target is $61.80. The highest price target for TRML is $74.00, while the lowest price target for TRML is $48.00. The average price target represents a forecasted upside of 244.29% from the current price of $17.95.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Buy	Buy	Buy	N/A
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$61.80	$61.80	$61.80	N/A
Forecasted Upside	244.29% Upside	181.45% Upside	127.84% Upside	N/A

Get Tourmaline Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.

Ad Stansberry Research

Get out of cash before the Fed's next meeting

"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."

Click here now to watch this exclusive interview

TRML Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TRML Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Tourmaline Bio Stock vs. The Competition

Type	Tourmaline Bio	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	244.29% Upside	3,123.40% Upside	9.09% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/14/2024	HC Wainwright 3 of 5 stars	Y. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$48.00	+231.03%
3/25/2024	Truist Financial 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$74.00	+209.88%
3/20/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$41.00 ➝ $72.00	+61.18%
12/7/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
10/31/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+236.70%
10/25/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$65.00	+446.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:31 AM ET.

TRML Forecast - Frequently Asked Questions

What is Tourmaline Bio's forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Tourmaline Bio is $61.80, with a high forecast of $74.00 and a low forecast of $48.00.
Should I buy or sell Tourmaline Bio stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tourmaline Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRML shares.
Does Tourmaline Bio's stock price have much upside?: According to analysts, Tourmaline Bio's stock has a predicted upside of 181.45% based on their 12-month stock forecasts.
What analysts cover Tourmaline Bio?: Tourmaline Bio has been rated by research analysts at HC Wainwright in the past 90 days.
Do Wall Street analysts like Tourmaline Bio more than its competitors?: Analysts like Tourmaline Bio more than other "medical" companies. The consensus rating for Tourmaline Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TRML compares to other companies.